Q-omics provides the consensus-scored MAEL profile across patient tissues and cancer cell-line models. MAEL expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MAEL is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, MAEL RNA expression shows 13,167 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, KICH, and TGCT as cancer lineages where MAEL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MAEL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MAEL survival associations across molecular data types. MAEL RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MAEL RNA expression–survival associations across cancer types. High MAEL expression shows unfavorable associations in LGG and LAML, but favorable associations in ACC, KIRC, SKCM and LUAD. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MAEL RNA expression.
This table summarizes MAEL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for MAEL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MAEL shows lower tumor expression in KICH, BLCA, UCEC and READ and higher tumor expression in BRCA and LIHC. The KICH box plot shows higher MAEL RNA expression in normal versus tumor tissue (log2 FC = −1.148, t-test p < 0.001).
This table shows molecular features associated with MAEL in patient tissues and cancer cell lines. In patient samples, MAEL shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MAEL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and CNS.
